Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29257625 | 0.88 | CSNK2A1 (0.37) | CSNK2A1CYP2A6GPR84HTR2ASLC6A4 | |
| SCHEMBL30408342 | 0.82 | CSNK2A1 (0.44) | CSNK2A1CYP2A6KCNH2KDM1AKDM1B | |
| SCHEMBL14810674 | 0.82 | CSNK2A1 (0.44) | CSNK2A1CYP2A6KCNH2KDM1AKDM1B | |
| SCHEMBL3369370 | 0.82 | CSNK2A1 (0.44) | CSNK2A1CYP2A6GPR84HTR2ASLC6A4 | |
| SCHEMBL24384654 | 0.79 | CSNK2A1 (0.44) | CSNK2A1CYP2A6KDM1AKDM1BESR1 | |
| SCHEMBL3365689 | 0.79 | CSNK2A1 (0.44) | CSNK2A1CYP2A6GPR84 | |
| SCHEMBL10472977 | 0.79 | CSNK2A1 (0.34) | CSNK2A1CYP2A6 | |
| SCHEMBL5107620 | 0.78 | HTR2A (0.44) | HTR2ASLC6A4KCNH2TDP1MAPT | |
| SCHEMBL8896950 | 0.77 | CYP2A6 (0.36) | CSNK2A1CYP2A6ESR1ESR2 | |
| SCHEMBL194793 | 0.75 | CD44 (0.37) | CSNK2A1CYP2A6TDP1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2889287-B1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | CELLTRION INC (KR) | 2016-08-31 | — | — | EP | disclosed |
| US-9278996-B2 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same | CELLTRION, INC. (KR) | 2016-03-08 | — | — | US | disclosed |
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | CELLTRION, INC. (KR) | 2015-08-13 | — | — | US | disclosed |
| EP-2889287-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | Celltrion, Inc. (KR) | 2015-07-01 | — | — | EP | disclosed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | DAD1, DDOST, SCD5 | CSNK2A1 1702/4885CYP2A6 1809/4885GPR84 4285/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CSNK2A1 2100/4885CYP2A6 1212/4885GPR84 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.